<p>肿瘤研究所公司（Oncology Institute, Inc.）已召开 2026 年第一季度财报电话会议。以下是会议的主要亮点。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>肿瘤研究所公司的最新财报电话会议整体语气乐观，管理层强调了强劲的收入增长、专业药房业务的扩展以及价值基础合同的增加。尽管承认利润率、按服务收费的收入和再融资风险面临压力，管理层仍强调了运营杠杆的改善、现金流轨迹的提升以及朝着可持续盈利能力的明确进展。</p>
<h2>强劲的收入增长</h2>
<p>肿瘤研究所报告 2026 年第一季度收入为 1.474 亿美元，同比增长 41.2%，这得益于按人头支付安排的扩展和专业药房业务量的增加。这一增长凸显了公司赢得新合同和深化价值基础肿瘤关系的能力，为其核心市场的更大规模奠定了基础。</p>
<h2>强劲的专业药房表现</h2>
<p>专业药房仍然是主要的增长引擎，带来了 8750 万美元的收入，占总收入的 59.4%，同比增长 77.6%，处方填充量激增约 103%。药房毛利润达到 1680 万美元，利润率为 19.2%，基本持平，表明药房平台在保持稳定的单位经济的同时高效扩展。</p>
<h2>按人头支付的势头和向价值基础护理的转变</h2>
<p>按人头支付的收入同比增长 54%，达到 2690 万美元，现在约占患者服务收入的 45.6%，而之前约为 33%。这一日益增长的价值基础合同组合表明，支付方越来越愿意将风险委托给肿瘤研究所，可能会随着时间的推移解锁更可预测的收入流和利润上升空间。</p>
<h2>盈利能力趋势改善和现金流展望</h2>
<p>盈利能力指标继续朝着正确的方向发展，调整后的 EBITDA 亏损从一年前的 510 万美元缩小至 240 万美元，而经营现金流改善至 230 万美元的流出，较去年同期的 500 万美元有所改善。管理层重申全年调整后 EBITDA 指导为 0 至 900 万美元，并显著提高自由现金流预期至正的 500 万至 1500 万美元，增强了对商业模式的信心。</p>
<h2>佛罗里达市场成就</h2>
<p>佛罗里达市场表现突出，在四墙 EBITDA 基础上实现盈利，并交付接近或略好于 2025 年委托群体 85% 的医疗损失率。基于这一成功，公司计划在第三季度扩展到 25 个县的约 200,000 个医疗保险优先生活者，强调佛罗里达在其模式验证中的重要角色。</p>
<h2>运营杠杆和 SG&amp;A 改善</h2>
<p>一般和行政费用总计 2820 万美元，绝对值上升，但占收入的比例从一年前的 24.3% 降至 19.1%，改善约 520 个基点。这一比例的下降反映了公司在扩展平台时运营杠杆的增长，表明增量增长应越来越多地流向底线。</p>
<h2>技术和节省成本的举措</h2>
<p>管理层强调了在收入周期、事前授权和呼叫中心运营中的人工智能驱动的努力，预计将在 2026 年实现约 200 万美元的运营费用节省。计划在第三季度推出的专有提供者门户预计将增强治疗路径遵循、利用管理和附加收入捕获，提供增量效率和利润优势。</p>
<h2>监管和项目认可</h2>
<p>肿瘤研究所指出，在最近的联邦肿瘤模型下，它在医疗保险支出中节省了近 200 万美元，展示了其综合护理方法的临床和经济价值。这些结果有助于验证其价值基础战略，并可能支持未来与寻求成本控制和质量结果的支付方和监管机构的讨论。</p>
<h2>按服务收费收入下降</h2>
<p>并非所有趋势都是有利的，尽管患者就诊量增加，按服务收费的收入同比下降约 10%，降至 3220 万美元，反映出故意的组合转变和更严格的药物管理。公司还对收款进行了保守的准备，并在 IV 药物渠道面临适度的价格压力，突显了传统基于量的收入流在短期内的逆风。</p>
<h2>患者服务毛利压缩</h2>
<p>患者服务的毛利率从一年前的 11.3% 下降至 9.7%，下降约 163 个基点，主要是由于委托合同的增加和对按服务收费应收款的保守处理。管理层将此视为新风险承担安排扩展时的暂时权衡，预计随着群体的成熟和运营效率的提升，利润率将改善。</p>
<h2>整体毛利略有下降</h2>
<p>公司整体毛利率从 16.5% 微降至 15.8%，受到低毛利委托业务比例增加和缺乏对上一年有利的非经常性回扣的压力。尽管这一变化较小，投资者将关注公司如何在实现量的增长和价值基础扩展的同时，平衡稳定并最终扩大毛利。</p>
<h2>第一季度的季节性和持续亏损</h2>
<p>管理层提醒投资者，第一季度通常由于免赔额重置和年度药物成本增加而季节性疲软，今年的结果再次受到影响。公司仍报告了 240 万美元的负调整 EBITDA 和负经营现金流，尽管这两个指标有所改善，表明结构性改善开始抵消季节性压力。</p>
<h2>每次药房填充的平均收入压力</h2>
<p>每家药房的平均收入同比下降约 12%，这是由于药品和支付方的组合发生变化，部分被填充量的急剧上升所抵消。管理层提到，随着各种政策变化的逐步实施，定价环境正在变化，强调在当前环境中，填充量增长和成本管理将是保持药房盈利能力的关键。</p>
<h2>杠杆和再融资风险</h2>
<p>流动性仍然充足，但并非无限，现金及现金等价物从年末的 3360 万美元下降至 3030 万美元，同时还有 8590 万美元的高级担保可转换票据未偿还。管理层透露，正在进行后期讨论，以在 2027 年到期之前再融资这些义务，这引入了一些执行风险，投资者将密切关注这一点以及运营进展。</p>
<h2>指引和前景展望</h2>
<p>展望未来，Oncology Institute 重申其 2026 年的收入展望为 6.3 亿至 6.5 亿美元，其中大约 1.5 亿美元来自于固定合同，毛利润为 9700 万至 1.07 亿美元，调整后的 EBITDA 在盈亏平衡和 900 万美元之间。公司还预计第二季度的调整后 EBITDA 将略微为负至盈亏平衡，预计全年自由现金流为 500 万至 1500 万美元，计划到年中将委托的医疗保险优先计划人数增加到约 20 万人，并重申预计通过人工智能举措实现的成本节省。</p>
<p>总体而言，财报电话会议描绘了一家正在转型但逐渐获得动力的公司，专科药房和固定合同的强劲增长超过了可控的利润和融资阻力。投资者希望看到持续盈利能力的进展、委托合同的执行以及再融资的清晰度，但升级的现金流展望表明该战略开始见效。</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

<p>Oncology Institute, Inc. 报告了 2026 年第一季度强劲的业绩，收入为 1.474 亿美元，同比增长 41.2%，主要得益于专科药房的增长和固定合同。专科药房的收入激增 77.6%，达到 8750 万美元。调整后的 EBITDA 亏损缩小至 240 万美元，现金流预期有所改善。佛罗里达市场实现盈利，公司计划扩大其医疗保险优势计划的覆盖人数。然而，按服务收费的收入下降了 10%，患者服务的利润率压缩至 9.7%。整体毛利率略微下降至 15.8%</p>

<p>Oncology Institute, Inc. ((TOI)) has held its Q1 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>肿瘤研究所公司（Oncology Institute, Inc.）已召开 2026 年第一季度财报电话会议。以下是会议的主要亮点。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Oncology Institute, Inc.’s latest earnings call struck an overall upbeat tone, with management highlighting strong revenue growth, scaling specialty pharmacy operations and expanding value-based contracts. While acknowledging pressures on margins, fee-for-service revenues and refinancing risk, executives emphasized improving operating leverage, better cash flow trajectory and clear progress toward sustainable profitability.</p>
<div class="lb-trans"><p>肿瘤研究所公司的最新财报电话会议整体语气乐观，管理层强调了强劲的收入增长、专业药房业务的扩展以及价值基础合同的增加。尽管承认利润率、按服务收费的收入和再融资风险面临压力，管理层仍强调了运营杠杆的改善、现金流轨迹的提升以及朝着可持续盈利能力的明确进展。</p>
</div><h2>Strong Top-Line Growth</h2>
<div class="lb-trans"><h2>强劲的收入增长</h2>
</div><p>Oncology Institute reported first-quarter 2026 revenue of $147.4 million, up 41.2% year over year, fueled by the expansion of capitated arrangements and higher specialty pharmacy volume. This growth underscores the company’s ability to win new contracts and deepen relationships in value-based oncology, positioning the business for greater scale in its core markets.</p>
<div class="lb-trans"><p>肿瘤研究所报告 2026 年第一季度收入为 1.474 亿美元，同比增长 41.2%，这得益于按人头支付安排的扩展和专业药房业务量的增加。这一增长凸显了公司赢得新合同和深化价值基础肿瘤关系的能力，为其核心市场的更大规模奠定了基础。</p>
</div><h2>Robust Specialty Pharmacy Performance</h2>
<div class="lb-trans"><h2>强劲的专业药房表现</h2>
</div><p>Specialty pharmacy remained the primary growth engine, delivering $87.5 million of revenue, or 59.4% of the total, up 77.6% from a year ago as prescription fills surged about 103%. Pharmacy gross profit reached $16.8 million with a 19.2% margin that was essentially flat, suggesting the pharmacy platform is scaling efficiently while maintaining stable unit economics.</p>
<div class="lb-trans"><p>专业药房仍然是主要的增长引擎，带来了 8750 万美元的收入，占总收入的 59.4%，同比增长 77.6%，处方填充量激增约 103%。药房毛利润达到 1680 万美元，利润率为 19.2%，基本持平，表明药房平台在保持稳定的单位经济的同时高效扩展。</p>
</div><h2>Capitation Momentum and Shift to Value-Based Care</h2>
<div class="lb-trans"><h2>按人头支付的势头和向价值基础护理的转变</h2>
</div><p>Capitated revenue climbed 54% year over year to $26.9 million and now accounts for roughly 45.6% of patient services revenue, versus about 33% previously. This growing mix of value-based contracts signals that payers are increasingly willing to delegate risk to Oncology Institute, potentially unlocking more predictable revenue streams and margin upside over time.</p>
<div class="lb-trans"><p>按人头支付的收入同比增长 54%，达到 2690 万美元，现在约占患者服务收入的 45.6%，而之前约为 33%。这一日益增长的价值基础合同组合表明，支付方越来越愿意将风险委托给肿瘤研究所，可能会随着时间的推移解锁更可预测的收入流和利润上升空间。</p>
</div><h2>Improved Profitability Trends and Cash Flow Outlook</h2>
<div class="lb-trans"><h2>盈利能力趋势改善和现金流展望</h2>
</div><p>Profitability metrics continued to trend in the right direction as adjusted EBITDA loss narrowed to $2.4 million from $5.1 million a year earlier, while operating cash flow improved to a $2.3 million outflow from $5.0 million. Management reaffirmed full-year adjusted EBITDA guidance of $0 to $9 million and notably lifted free cash flow expectations to a positive $5 million to $15 million, reinforcing confidence in the business model.</p>
<div class="lb-trans"><p>盈利能力指标继续朝着正确的方向发展，调整后的 EBITDA 亏损从一年前的 510 万美元缩小至 240 万美元，而经营现金流改善至 230 万美元的流出，较去年同期的 500 万美元有所改善。管理层重申全年调整后 EBITDA 指导为 0 至 900 万美元，并显著提高自由现金流预期至正的 500 万至 1500 万美元，增强了对商业模式的信心。</p>
</div><h2>Florida Market Achievement</h2>
<div class="lb-trans"><h2>佛罗里达市场成就</h2>
</div><p>The Florida market emerged as a standout, turning profitable on a four-wall EBITDA basis and delivering a medical loss ratio near or slightly better than the 85% target for the 2025 delegated cohort. Building on this success, the company plans to expand to around 200,000 Medicare Advantage lives under delegated capitation across 25 counties by the third quarter, underscoring Florida’s role as a proving ground for its model.</p>
<div class="lb-trans"><p>佛罗里达市场表现突出，在四墙 EBITDA 基础上实现盈利，并交付接近或略好于 2025 年委托群体 85% 的医疗损失率。基于这一成功，公司计划在第三季度扩展到 25 个县的约 200,000 个医疗保险优先生活者，强调佛罗里达在其模式验证中的重要角色。</p>
</div><h2>Operating Leverage and SG&amp;A Improvement</h2>
<div class="lb-trans"><h2>运营杠杆和 SG&amp;A 改善</h2>
</div><p>General and administrative expenses totaled $28.2 million, up in absolute terms but down to 19.1% of revenue from 24.3% a year ago, a roughly 520-basis-point improvement. This drop as a share of revenue reflects growing operating leverage as the company scales its platform, suggesting that incremental growth should increasingly flow through to the bottom line.</p>
<div class="lb-trans"><p>一般和行政费用总计 2820 万美元，绝对值上升，但占收入的比例从一年前的 24.3% 降至 19.1%，改善约 520 个基点。这一比例的下降反映了公司在扩展平台时运营杠杆的增长，表明增量增长应越来越多地流向底线。</p>
</div><h2>Technology and Cost-Savings Initiatives</h2>
<div class="lb-trans"><h2>技术和节省成本的举措</h2>
</div><p>Management highlighted AI-enabled efforts in revenue cycle, prior authorizations and call center operations that are on track to deliver about $2 million of operating expense savings in 2026. A proprietary provider portal, slated for launch in the third quarter, is expected to enhance treatment pathway adherence, utilization management and ancillary revenue capture, offering incremental efficiency and margin benefits.</p>
<div class="lb-trans"><p>管理层强调了在收入周期、事前授权和呼叫中心运营中的人工智能驱动的努力，预计将在 2026 年实现约 200 万美元的运营费用节省。计划在第三季度推出的专有提供者门户预计将增强治疗路径遵循、利用管理和附加收入捕获，提供增量效率和利润优势。</p>
</div><h2>Regulatory and Program Recognition</h2>
<div class="lb-trans"><h2>监管和项目认可</h2>
</div><p>Oncology Institute noted that it saved nearly $2 million in Medicare spending under a recent period of a federal oncology model, showcasing the clinical and economic value of its integrated care approach. Such results help validate its value-based strategy and could support future discussions with payers and regulators seeking both cost control and quality outcomes.</p>
<div class="lb-trans"><p>肿瘤研究所指出，在最近的联邦肿瘤模型下，它在医疗保险支出中节省了近 200 万美元，展示了其综合护理方法的临床和经济价值。这些结果有助于验证其价值基础战略，并可能支持未来与寻求成本控制和质量结果的支付方和监管机构的讨论。</p>
</div><h2>Fee-for-Service Revenue Decline</h2>
<div class="lb-trans"><h2>按服务收费收入下降</h2>
</div><p>Not all trends were favorable, as fee-for-service revenue fell about 10% year over year to $32.2 million despite higher patient visit volumes, reflecting a deliberate mix shift and tighter drug management. The company also booked conservative reserves against collections and faced modest pricing pressure in the IV drug channel, underscoring near-term headwinds in traditional volume-based revenue streams.</p>
<div class="lb-trans"><p>并非所有趋势都是有利的，尽管患者就诊量增加，按服务收费的收入同比下降约 10%，降至 3220 万美元，反映出故意的组合转变和更严格的药物管理。公司还对收款进行了保守的准备，并在 IV 药物渠道面临适度的价格压力，突显了传统基于量的收入流在短期内的逆风。</p>
</div><h2>Patient Services Margin Compression</h2>
<div class="lb-trans"><h2>患者服务毛利压缩</h2>
</div><p>Patient services gross margin slipped to 9.7% from 11.3% a year earlier, a decline of roughly 163 basis points driven by ramping delegated contracts and conservative treatment of fee-for-service receivables. Management framed this as a temporary trade-off as new risk-bearing arrangements scale, with expectations that margins improve as cohorts mature and operational efficiencies take hold.</p>
<div class="lb-trans"><p>患者服务的毛利率从一年前的 11.3% 下降至 9.7%，下降约 163 个基点，主要是由于委托合同的增加和对按服务收费应收款的保守处理。管理层将此视为新风险承担安排扩展时的暂时权衡，预计随着群体的成熟和运营效率的提升，利润率将改善。</p>
</div><h2>Overall Gross Margin Slightly Lower</h2>
<div class="lb-trans"><h2>整体毛利略有下降</h2>
</div><p>Company-wide gross margin edged down to 15.8% from 16.5%, pressured by a greater mix of lower-margin delegated business and the absence of a nonrecurring rebate that benefited the prior year. While the shift is modest, investors will be watching how the company balances volume growth and value-based expansion with the need to stabilize and eventually expand gross profitability.</p>
<div class="lb-trans"><p>公司整体毛利率从 16.5% 微降至 15.8%，受到低毛利委托业务比例增加和缺乏对上一年有利的非经常性回扣的压力。尽管这一变化较小，投资者将关注公司如何在实现量的增长和价值基础扩展的同时，平衡稳定并最终扩大毛利。</p>
</div><h2>Q1 Seasonality and Ongoing Loss</h2>
<div class="lb-trans"><h2>第一季度的季节性和持续亏损</h2>
</div><p>Management reminded investors that the first quarter is typically seasonally soft due to deductible resets and annual drug cost increases, which weighed on results again this year. The company still reported a negative adjusted EBITDA of $2.4 million and negative operating cash flow, though both metrics improved, indicating that structural improvements are starting to offset seasonal pressure.</p>
<div class="lb-trans"><p>管理层提醒投资者，第一季度通常由于免赔额重置和年度药物成本增加而季节性疲软，今年的结果再次受到影响。公司仍报告了 240 万美元的负调整 EBITDA 和负经营现金流，尽管这两个指标有所改善，表明结构性改善开始抵消季节性压力。</p>
</div><h2>Pressure on Average Revenue per Pharmacy Fill</h2>
<div class="lb-trans"><h2>每次药房填充的平均收入压力</h2>
</div><p>Average revenue per pharmacy fill fell about 12% year over year as the mix of drugs and payers evolved, partly offset by the sharp rise in fill volumes. Management cited a changing pricing environment as various policy changes phase in, highlighting that volume growth and cost management will be key to preserving pharmacy profitability in the current environment.</p>
<div class="lb-trans"><p>每家药房的平均收入同比下降约 12%，这是由于药品和支付方的组合发生变化，部分被填充量的急剧上升所抵消。管理层提到，随着各种政策变化的逐步实施，定价环境正在变化，强调在当前环境中，填充量增长和成本管理将是保持药房盈利能力的关键。</p>
</div><h2>Leverage and Refinancing Risk</h2>
<div class="lb-trans"><h2>杠杆和再融资风险</h2>
</div><p>Liquidity remains adequate but not limitless, with cash and equivalents dipping to $30.3 million from $33.6 million at year-end and $85.9 million of senior secured convertible notes outstanding. Management disclosed that it is in late-stage discussions to refinance these obligations before their 2027 maturity, introducing some execution risk that investors will closely track alongside operating progress.</p>
<div class="lb-trans"><p>流动性仍然充足，但并非无限，现金及现金等价物从年末的 3360 万美元下降至 3030 万美元，同时还有 8590 万美元的高级担保可转换票据未偿还。管理层透露，正在进行后期讨论，以在 2027 年到期之前再融资这些义务，这引入了一些执行风险，投资者将密切关注这一点以及运营进展。</p>
</div><h2>Guidance and Forward Outlook</h2>
<div class="lb-trans"><h2>指引和前景展望</h2>
</div><p>Looking ahead, Oncology Institute reaffirmed its 2026 revenue outlook of $630 million to $650 million, including roughly $150 million from capitated contracts, with gross profit of $97 million to $107 million and adjusted EBITDA between break-even and $9 million. The company also guided to modestly negative to breakeven adjusted EBITDA in the second quarter, expects free cash flow of $5 million to $15 million for the year, plans to grow delegated Medicare Advantage lives to about 200,000 by midyear and reiterated expected cost savings from AI initiatives.</p>
<div class="lb-trans"><p>展望未来，Oncology Institute 重申其 2026 年的收入展望为 6.3 亿至 6.5 亿美元，其中大约 1.5 亿美元来自于固定合同，毛利润为 9700 万至 1.07 亿美元，调整后的 EBITDA 在盈亏平衡和 900 万美元之间。公司还预计第二季度的调整后 EBITDA 将略微为负至盈亏平衡，预计全年自由现金流为 500 万至 1500 万美元，计划到年中将委托的医疗保险优先计划人数增加到约 20 万人，并重申预计通过人工智能举措实现的成本节省。</p>
</div><p>On balance, the earnings call painted a picture of a company in transition but gaining traction, with robust growth in specialty pharmacy and capitation outpacing manageable margin and financing headwinds. Investors will want to see continued progress toward sustained profitability, execution on delegated contracts and clarity around refinancing, but the upgraded cash flow outlook suggests the strategy is beginning to pay off.</p>
<div class="lb-trans"><p>总体而言，财报电话会议描绘了一家正在转型但逐渐获得动力的公司，专科药房和固定合同的强劲增长超过了可控的利润和融资阻力。投资者希望看到持续盈利能力的进展、委托合同的执行以及再融资的清晰度，但升级的现金流展望表明该战略开始见效。</p>
</div>

肿瘤研究所的收益电话会议突出了其增长转型